Elanco CEO awarded deferred stock units

Elanco Animal Health Inc. reported an insider equity award for its President, CEO and Director, Jeffrey N. Simmons, on February 6, 2026.

Accepted by SEC EDGAR 02/10/2026 - 04:32 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Elanco Animal Health Inc. reported an insider equity award for its President, CEO and Director, Jeffrey N. Simmons, on February 6, 2026. He acquired 109.8905 deferred stock units at $25.2 per unit, bringing his directly held deferred stock units to 19,068.9056.

Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units settle in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.

Insider Trade Summary

Grant/Award: 109.8905 shares

Grant/Award 1 txn

Insider Simmons Jeffrey N

Role PRESIDENT, CEO AND DIRECTOR

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	109.8905	$25.20	$3K

Holdings After Transaction: Deferred Stock Units — 19,068.9056 contracts (Direct)

Holdings Before and After: Deferred Stock Units, 18,959.0151 to 19,068.9056 contracts (Direct)

Footnotes (2)

1. F1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
2. F2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Elanco (ELAN) report for Jeffrey N. Simmons?

Elanco reported that President and CEO Jeffrey N. Simmons acquired 109.8905 deferred stock units on February 6, 2026, at $25.2 per unit. This increased his directly held deferred stock units to 19,068.9056 under the company’s Executive Deferral and Stock Match Plan.

How many deferred stock units does Jeffrey N. Simmons hold after this transaction?

After the February 6, 2026 transaction, Jeffrey N. Simmons beneficially owns 19,068.9056 deferred stock units directly. These units represent rights that can settle in either Elanco common stock or cash, subject to the plan’s terms and future settlement timing.

What is the value per deferred stock unit in the Elanco (ELAN) Form 4 filing?

The Form 4 shows a transaction price of $25.2 per deferred stock unit. Simmons received 109.8905 units at this price, recorded as an acquisition under transaction code “A,” reflecting an award rather than an open-market purchase or sale.

What does each Elanco deferred stock unit reported in this Form 4 represent?

Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. The actual form of settlement depends on the Executive Deferral and Stock Match Plan and occurs after employment ends or in a designated future year.

When will Jeffrey N. Simmons’ Elanco deferred stock units settle?

The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year. Settlement timing and form are governed by the company’s Executive Deferral and Stock Match Plan terms.

Is the Elanco (ELAN) Form 4 transaction a direct or indirect holding for Simmons?

The Form 4 classifies Simmons’ 19,068.9056 deferred stock units as directly held, marked with ownership code “D.” No nature-of-ownership footnote indicates holding through another entity, so the position is reported as his direct beneficial ownership interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simmons Jeffrey N

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CEO AND DIRECTOR

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units	(1)	02/06/2026		A		109.8905		(2)	(2)	Common Stock	109.8905	$25.2	19,068.9056	D

Explanation of Responses:

1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.

2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.